EP055 In-Situ Forming Implant
- User: Male
- Hormonal: Non-Hormonal
-
Delivery type:
- Subdermal
-
Intended Duration:
- Short-Acting
- Development Stage: Discovery & Early Development
- Developer(s)/researcher(s): University of North Carolina
Details
- API: EP055
- Target: EPPIN
-
Mechanism of Action:
- Inhibition of Sperm Motility
- Inhibition of Sperm Capacitation
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Not Potential MPT
- Promising Attributes: Not Yet Established - Concept is in Early Development
Product Status
Active/Recent Formulation Research
History
2025: UNC Chapel Hill and Eppin Pharma publish results of preliminary evaluation intended to determine the potential of EP055-based in-situ forming implants for male contraception.